Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/2025
Type: Artigo de periódico
Title: Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles
Author: Minarini, Paulo R. R.
de Souza, Ana O.
Soares, Edson G.
Barata, Lauro E. S.
Silva, Celio L.
Bentley, Maria Vitoria L. B.
Abstract: Conventional treatment of tuberculosis (TB) demands a long course therapy (6 months), known to originate multiple drug resistant strains (MDR-TB), which emphasizes the urgent need for new antituberculous drugs. The purpose of this study was to investigate a novel treatment for TB meant to improve patient compliance by reducing drug dosage frequency. Polymeric microparticles containing the synthetic analogue of neolignan, 1-phenyl-2-phenoxiethanone (LS-2), were obtained by a method of emulsification and solvent evaporation and chemically characterized. Only representative LS-2-loaded microparticles were considered for further studies involving experimental murine TB induced by Mycobacterium tuberculosis H37Rv ATCC 27294. The LS-2-loaded microparticles were spherical in shape, had a smooth wall and showed an encapsulation efficiency of 93% in addition to displaying sustained release. Chemotherapeutic potential of LS-2 entrapped in microparticles was comparable to control groups. These findings are encouraging and indicate that LS-2-loaded microparticles are a potential alternative to conventional chemotherapy of TB.
Subject: Synthetic analogue of neolignan
1-phenyl-2-phenoxiethanone
PLGA microparticles
tuberculosis
antitubercular agent
Editor: Informa Healthcare
Citation: Drug development and Industrial Pharmacy. Informa Healthcare, v.38, n.3, p.259-263, 2012
Rights: fechado
Identifier DOI: 10.3109/03639045.2011.598535
Date Issue: 2012
Appears in Collections:IQ - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.